Core Viewpoint - A class action lawsuit has been filed against ICON Public Limited Company for alleged violations of securities laws, claiming the company made false and misleading statements that led to investor losses [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between July 27, 2023, and October 23, 2024, during which investors are encouraged to contact the Schall Law Firm for participation [2]. - The complaint alleges that ICON's misleading statements were related to its business performance and customer engagements, which were negatively impacted by funding limitations faced by its customer base [4]. Group 2: Company Performance Issues - ICON's Functional Service Provision (FSP) and hybrid models did not safeguard the company from market downturns, leading to contract cancellations and reduced engagements from clients [4]. - The two largest clients of ICON began diversifying their contract research organization (CRO) providers, which further contributed to the company's declining business [4].

Core Viewpoint - ICON plc reported a mixed performance for Q1 2025, with adjusted earnings per share beating estimates but revenues falling short, reflecting ongoing challenges in the clinical development market [7]. Group 1: Earnings Performance - Adjusted earnings per share for Q1 2025 were $3.19, down 8.1% year-over-year, but exceeded the Zacks Consensus Estimate by 3.5% [1] - GAAP earnings per share were $1.90, a decrease of 15.6% from the previous year [1]. Group 2: Revenue Analysis - Total revenues decreased by 4.3% year-over-year to $2.00 billion, and fell short of the Zacks Consensus Estimate by 0.5% [2]. - Gross business wins for the quarter were $2.68 billion, with cancellations totaling $659 million, resulting in net business wins of $2.02 billion and a book-to-bill ratio of 1.01 [2]. Group 3: Margin and Expense Insights - Gross profit declined by 9.8% year-over-year to $558.7 million, with gross margin contracting by 170 basis points to 27.9% [3]. - Selling, general and administrative expenses rose by 11.9% to $198.4 million [3]. - Adjusted operating income was $360.3 million, reflecting an 18.4% year-over-year decrease, with adjusted operating margin contracting by 313 basis points to 18% [3]. Group 4: Cash Position - At the end of Q1, ICON had cash and cash equivalents of $526.7 million, down from $538.8 million at the end of Q4 2024, with a net debt balance of $2.9 billion [4]. - Cumulative cash flow from operating activities was $268.2 million, compared to $327.1 million in the prior-year period [4]. Group 5: 2025 Guidance - The company updated its full-year 2025 revenue guidance to a range of $7.75 billion to $8.15 billion, reflecting a year-over-year decrease of 6.4% to 1.6% [5]. - Adjusted EPS for the year is anticipated to be between $12.75 and $14.25, indicating a year-over-year change of -8.9% to 1.8% [6]. Group 6: Market Context - The performance reflects volatility and caution in the clinical development market, with bookings below expectations due to delays in customer decision-making and high cancellation rates [7]. - The updated financial outlook excludes two large next-generation COVID-19 vaccine trials, indicating a strategic shift in focus [7].

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2 billion, representing a year-on-year decrease of 4.3% or 3.2% on a constant currency basis [21] - Adjusted gross margin for the quarter was 28.2%, down from 29.9% in Q1 2024 [21] - Adjusted EBITDA was $390.7 million, or 19.5% of revenue, compared to $444 million or 21.2% of revenue in the prior year [21] - Adjusted net income for the quarter was $258.3 million, a margin of 12.9%, equating to adjusted earnings per share of $3.19, an 8.1% decrease year-over-year [23] - U.S. GAAP net income was $154.2 million, or $1.90 per diluted share, down 15.6% from $2.25 per share in the prior year [24] Business Line Data and Key Metrics Changes - In biotech, there was a significant increase in overall opportunities, but this was offset by an increase in canceled RFPs [10][11] - In large pharma, RFP opportunities were muted, but the success rate remained high, indicating strong partnership positioning [11] - Book-to-bill ratio decreased to 1.01x due to elevated cancellations [11] Market Data and Key Metrics Changes - Customer concentration remained stable, with the top five customers representing 24.9% of revenue and the top 10 representing 40.2% [21] - Cancellations were elevated across customer segments, reflecting broader market dynamics [11][30] Company Strategy and Development Direction - The company is focused on navigating market volatility while capitalizing on opportunities to improve its market position [9][10] - There is a strategic emphasis on operational utilization and cost control, resulting in better-than-expected adjusted EBITDA margin performance [13] - The company plans to continue share repurchases and evaluate strategic M&A opportunities [19][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism, noting mixed demand from large pharma and ongoing challenges in the biotech funding environment [7][8] - Elevated cancellations are expected to persist, impacting near-term revenue guidance [12][36] - The company remains focused on enhancing customer delivery and leveraging digital innovation to improve operational efficiencies [17][19] Other Important Information - The company repurchased $250 million in shares during Q1 2025, with plans to continue share buybacks [25][26] - New AI-enabled tools were released to enhance clinical trial processes, demonstrating a commitment to digital innovation [17] Q&A Session Summary Question: About elevated cancellations and their impact - Management indicated that cancellations were generally elevated across customer segments without any unusual patterns [28][30] Question: On the overall backdrop and future spending - Management expects elevated cancellation levels to continue but does not foresee a significant increase beyond current levels [34][36] Question: Regarding revenue trends and pricing sensitivity - Management acknowledged increased price sensitivity among smaller customers and noted a modest uptick in RFP flow in biotech, but emphasized that the quality of RFPs varies [40][46] Question: On the clinical development landscape in China - Management highlighted the growing R&D capabilities in China and the company's strong position to participate in clinical trials there [76][78] Question: About the impact of COVID-related cancellations on revenue guidance - Management clarified that the $350 million reduction in guidance was primarily due to two next-generation COVID trials being removed from the outlook [81][100]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2 billion, representing a year-on-year decrease of 4.3% or 3.2% on a constant currency basis [22] - Adjusted gross margin for the quarter was 28.2%, down from 29.9% in Q1 2024 [22] - Adjusted EBITDA was $390.7 million, or 19.5% of revenue, compared to $444 million or 21.2% in the same period last year [23] - Adjusted net income for the quarter was $258.3 million, a margin of 12.9%, equating to adjusted earnings per share of $3.19, down 8.1% year-over-year [24] - U.S. GAAP net income was $154.2 million, or $1.90 per diluted share, a decrease of 15.6% from the prior year [25] - Cash from operating activities was $268.2 million, with free cash flow of $239.3 million [26] Business Line Data and Key Metrics Changes - In biotech, there was a significant increase in overall opportunities, but this was offset by an increase in canceled RFPs [11] - In large pharma, RFP opportunities were muted, but the success rate remained high, indicating strong partnership positioning [12] - Book-to-bill ratio decreased to 1.01x due to elevated cancellations [12] Market Data and Key Metrics Changes - Customer concentration remained stable, with the top five customers representing 24.9% of revenue [22] - Cancellations were elevated across customer segments, reflecting broader market dynamics [30] Company Strategy and Development Direction - The company is focused on navigating a period of uncertainty while capitalizing on opportunities to improve its market position [10] - There is an emphasis on operational utilization and cost control to manage the business effectively [14] - The company plans to continue share repurchases and evaluate strategic M&A opportunities [19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism, noting mixed demand from large pharma and ongoing challenges in the biotech sector [9] - Elevated cancellations are expected to continue, impacting revenue guidance for the year [36] - The company remains focused on enhancing customer delivery and leveraging technology to improve operational efficiencies [18] Other Important Information - The company repurchased $250 million in shares during Q1 2025, with plans to remain active in share buybacks [26] - Two new AI-enabled tools were released to enhance clinical trial processes [18] Q&A Session Summary Question: About elevated cancellations - Management indicated that cancellations were generally elevated across customer segments, with no unusual patterns in specific groups [30][31] Question: On the overall backdrop and cancellations - Management expects elevated cancellations to continue, with a significant cancellation from a BARDA study anticipated in Q2 [36][39] Question: Regarding revenue and pricing pressures - Management noted that while there is increased competition in biotech, win rates in large pharma remain healthy [47] Question: On clinical development opportunities in China - Management highlighted the growing R&D capabilities in China and the company's strong position to participate in clinical trials there [80] Question: About the impact of COVID-related cancellations - Management clarified that the $350 million in anticipated revenue from COVID studies has been adjusted in the revenue guidance for 2025 [101][102]

Core Viewpoint - Icon PLC reported quarterly earnings of $3.19 per share, exceeding the Zacks Consensus Estimate of $3.08 per share, but down from $3.47 per share a year ago, indicating a 8.1% year-over-year decline [1] - The company posted revenues of $2 billion for the quarter, missing the Zacks Consensus Estimate by 0.58% and down from $2.09 billion year-over-year, reflecting a 4.3% decrease [2] Group 1: Earnings Performance - Icon PLC achieved an earnings surprise of 3.57% for the recent quarter, having previously reported earnings of $3.43 per share against an expectation of $3.42 per share, resulting in a surprise of 0.29% [1][2] - Over the last four quarters, the company has surpassed consensus EPS estimates three times [2] Group 2: Revenue Insights - The company has topped consensus revenue estimates only once in the last four quarters, indicating challenges in revenue performance [2] - The current consensus EPS estimate for the upcoming quarter is $3.25, with expected revenues of $2.05 billion, while the estimate for the current fiscal year is $13.48 on $8.21 billion in revenues [7] Group 3: Stock Performance and Outlook - Icon PLC shares have declined approximately 28.8% since the beginning of the year, contrasting with the S&P 500's decline of 5.5% [3] - The estimate revisions trend for Icon PLC is currently unfavorable, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] Group 4: Industry Context - The Medical Services industry, to which Icon PLC belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a relatively strong position within the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

ICON plc Q1 2025 Results Period Ended March 31, 2025 Forward Looking Statement Statements included in this presentation which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Forward-looking statements include statements regarding our financial guidance and outlook, and may be identified by the use of future tense or other forward-looking words s ...

Financial Performance - First quarter 2025 revenue was $2,001.3 million, a decrease of 4.3% compared to Q1 2024[6] - GAAP net income for Q1 2025 was $154.2 million, resulting in diluted earnings per share of $1.90, down 15.6% year over year[7] - Adjusted EBITDA for Q1 2025 was $390.7 million, representing 19.5% of revenue, a decrease of 12.0% from Q1 2024[8] - Net income for the three months ended March 31, 2025, was $154,151,000, a decrease of 17.7% compared to $187,438,000 for the same period in 2024[23] - Adjusted EBITDA for the three months ended March 31, 2025, was $390,658,000, down 12.1% from $444,036,000 in the prior year[25] - Adjusted net income for the three months ended March 31, 2025, was $258,269,000, a decrease of 10.5% from $288,513,000 in 2024[25] Guidance and Projections - Full-year 2025 revenue guidance is updated to a range of $7,750 - $8,150 million, reflecting a year-over-year decrease of 6.4% to 1.6%[5] - Adjusted diluted earnings per share guidance for 2025 is now projected to be between $12.75 and $14.25, indicating a year-over-year change of -8.9% to +1.8%[9] Cash Flow and Capital Expenditures - Cash generated from operating activities in Q1 2025 was $268.2 million, with capital expenditures of $28.9 million[9] - Cash flows provided by operating activities decreased to $268,240,000 from $327,076,000, reflecting a decline of 18% year-over-year[23] - The company reported a net cash used in financing activities of $252,832,000, compared to $263,699,000 in the same period last year[23] - Cash and cash equivalents at the end of the period were $526,698,000, down from $396,082,000 at the end of the same period in 2024[23] Debt and Financial Ratios - As of March 31, 2025, net debt was $2.9 billion, with a net debt to adjusted EBITDA ratio of 1.7x[9] - The effective tax rate on adjusted net income for Q1 2025 was 16.5%[9] Shareholder Actions - The company repurchased ordinary shares amounting to $250,000,000 during the quarter, reflecting a strategic move to enhance shareholder value[23] - The diluted weighted average number of ordinary shares outstanding decreased to 80,924,355 from 83,249,303, indicating a reduction of approximately 2.8%[25] Business Operations - Net business wins in Q1 2025 were $2,022 million, with a book-to-bill ratio of 1.01[9] - The closing backlog as of March 31, 2025, was $24.7 billion, an increase of 6.0% year over year[9] - The company incurred restructuring charges of $39,346,000 during the quarter, which were not present in the same period last year[25] Currency Impact - The effect of exchange rate movements on cash resulted in a positive impact of $9,787,000 compared to a negative impact of $6,032,000 in the prior year[23]

Core Viewpoint - A class action securities lawsuit has been filed against ICON Public Limited Company, alleging securities fraud that negatively impacted investors between July 27, 2023, and January 13, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations affecting its client base [2]. - It is alleged that ICON's service offerings were inadequate to protect the company from a significant market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools, not reflecting actual client demand [2]. - Customers of ICON are said to have canceled contracts, limited engagements, and delayed clinical trial work, failing to enter new contracts at historical rates [2]. - The two largest customers of ICON were diversifying their clinical research organization providers away from the company [2]. - As a result of these issues, ICON's reported business metrics misrepresented actual client demand for its services [2]. - The company was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until April 11, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - ICON PLC is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and undisclosed material losses impacting its business operations [1][3]. Company Overview - ICON PLC is identified as a clinical research organization (CRO) [2][3]. Allegations in the Lawsuit - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations affecting its client base [3]. - It is alleged that ICON's Functional Service Provision (FSP) and hybrid model offerings were inadequate to mitigate the effects of a significant market downturn [3]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than indicative of actual client demand [3]. - Customers of ICON are said to have canceled contracts, limited engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [3]. - The two largest customers of ICON were diversifying their CRO providers away from ICON [3]. - As a result of these issues, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [3]. - Consequently, ICON was tracking significantly below the 2024 revenue and EPS guidance issued during the Class Period, which lacked a reasonable factual basis [3]. Financial Performance - On October 23, 2024, ICON reported quarterly revenues of $2.03 billion, missing consensus estimates of $2.13 billion by over $100 million [4]. - The quarterly net new business wins declined to $2.3 billion from $2.6 billion in the prior quarter, and the book-to-bill ratio fell to 1.15 from 1.22 [4]. - The CEO indicated that two large pharmaceutical customers had curtailed upcoming FSP trial work due to ongoing cost containment measures, which would negatively impact financial performance [4]. - Following this news, the price of ICON ordinary shares dropped by more than 20% over two trading sessions [4].

Core Viewpoint - A class action securities lawsuit has been filed against ICON Public Limited Company, alleging securities fraud that negatively impacted investors between July 27, 2023, and January 13, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that ICON concealed significant business losses due to customer cost reduction measures and funding limitations affecting its client base [2]. - It is alleged that ICON's service offerings were inadequate to mitigate the effects of a market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than reflecting actual client demand [2]. - Customers of ICON are said to have canceled contracts, reduced engagements, and delayed clinical trial work, leading to a decline in new contracts [2]. - The two largest customers of ICON were diversifying their clinical research providers away from the company [2]. - As a result of these issues, ICON's reported business metrics misrepresented actual client demand for its services [2]. - The company was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until April 11, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].